Ohr Pharmaceutical Announces Successful End of Phase II

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD

Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months

Phase III Trials to Commence in the First Half of 2015

NEW YORK, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP ), an ophthalmology research and development company, today announced details of the planned pivotal Phase III registration trials for Squalamine Eye Drops (OHR-102) in the treatment of wet age-related macular degeneration (wet AMD). The trials are being designed based on guidance provided by the U.S. Food and Drug Administration (FDA) at a recent "end of Phase II" meeting. The FDA has agreed with Ohr on a 9 month primary efficacy endpoint based on the proportion of patients achieving a ≥3 line gain in visual acuity. In the interim analysis of the ongoing Phase II IMPACT study, more than twice the proportion of patients achieved ≥3 line gains in visual acuity at 9 months with the combination of OHR-102 eye drops and Lucentis ® as compared to the Lucentis monotherapy group (overall p=0.025, classic lesions p=0.007). Two identical Phase III studies will be performed. The Company plans to initiate the Phase III trials in the first half of 2015 with the goal of submitting a New Drug Application (NDA) following collection and analysis of the 9 month primary efficacy data.

"Our recent meeting has provided us with valuable input to formulate a clear regulatory strategy for OHR-102," said Dr. Irach Taraporewala, President and Chief Executive Officer of Ohr. "Importantly, the Agency has agreed with our plan to use visual acuity, as defined by gains of ≥3 lines at 9 months, as the primary endpoint in Phase III trials. Visual acuity is the most clinically relevant endpoint for retinal disease."

"Data from the IMPACT Phase II study demonstrated improvements in best-corrected visual acuity (BCVA) and ≥3 line gains using the combination of OHR-102 and Lucentis as compared to the Lucentis monotherapy group at all timepoints from 4 to 38 weeks. We believe this robust and rapid response to OHR-102 is a result of its potent inhibition of multiple angiogenic targets," said Dr. Jason Slakter, Chief Medical Officer of Ohr and retina specialist. "Considering that the Phase III primary endpoint will be at the same 9 month timepoint as the Phase II study, we believe we have set a very realistic goal of achieving a similar outcome in the planned Phase III trials."

The Phase III trials for Squalamine eye drops are being designed to measure the efficacy of combination therapy with OHR-102 eye drops plus Lucentis injections compared with Lucentis monotherapy at 9 months. All patients will be followed for safety for 2 years. The primary endpoint will be a measure of improvement in visual acuity, as defined by the proportion of patients achieving gains of ≥3 lines or more on the early treatment diabetic retinopathy study chart. During the first year of the study, patients will be randomized 1:1 to receive monthly Lucentis plus OHR-102 (Squalamine eye drops) twice a day or Lucentis plus placebo. During the second year they will receive Lucentis PRN (as needed) plus OHR-102 or placebo twice a day.

About Squalamine Eye Drops (OHR-102)

Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, which counteracts multiple growth factors and pathways implicated in the angiogenic process, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF). Ohr Pharmaceutical has developed a novel eye drop formulation of Squalamine (OHR-102) for the treatment of wet AMD, designed for convenient, patient self-administration, which may provide clinical utility for this patient population and other back-of-the-eye disorders. In May 2012, the Squalamine eye drop program was granted Fast Track Designation by the FDA. Interim Phase II data from the ongoing IMPACT study has demonstrated benefit in visual function versus placebo across multiple standard parameters. Three additional investigator sponsored trials are evaluating Squalamine eye drops for the treatment of proliferative diabetic retinopathy, retinal vein occlusion, and diabetic macular edema, and two Phase III studies in wet AMD are expected to be initiated in the first half of calendar 2015.

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr is developing a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The lead sustained release program in glaucoma is proceeding under a collaboration with a large global pharmaceutical company. Additional information on the company may be found at www.ohrpharmaceutical.com .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the safety and efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Lucentis ® is a registered trademark of Genentech, Inc.

CORPORATE CONTACT: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 LifeSci Advisors, LLC Michael Rice 646-597-6979

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 163

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 129

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 120

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 25

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 74

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

Joseph Margolis Shows Strong Faith in Extra Space Storage

Updated Category News Views 133

Joseph Margolis Shows Strong Faith in Extra Space Storage Recently, a significant insider purchase was conducted by Joseph Margolis, who holds the position of Chief Executive Officer at Extra Space Storage (EXR). According to the latest SEC filing, Margolis acquired 27,741 shares of the company, amounting to a considerable investment of $4,232,166. The market had a...

Continue Reading
Investigation Into Arcadium Lithium Sale Sparks Concerns

Updated Category News Views 192

Investigation Launched into Arcadium Lithium Shareholder Rights The former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., is leading an inquiry regarding an important corporate transaction involving Arcadium Lithium plc (NYSE: ALTM). This investigation, undertaken by the law firm Kahn Swick & Foti, LLC, seeks to assess whether the terms of the proposed sale to...

Continue Reading
Actian Introduces Advanced Federated Data Catalog for Businesses

Updated Category News Views 148

Actian Launches Innovative Federated Data Catalog Actian, the data and analytics division of HCLSoftware, is setting new standards in data management with the introduction of the Actian Zeenea Federated Data Catalog. This advanced platform simplifies data discovery, empowering users across enterprises to harness valuable data resources effectively. With the acquisition of...

Continue Reading
Oil-Dri Corporation Reports Impressive Second Quarter Growth

Updated Category News Views 123

Oil-Dri Corporation Achieves Significant Growth Oil-Dri Corporation of America (NYSE: ODC), a reputable name in the production and marketing of sorbent mineral products, has shared its impressive financial performance for the second quarter of fiscal 2025, marking substantial growth for the company. Financial Highlights of the Second Quarter During this reporting period,...

Continue Reading
Power Metallic: Drill Assays Fuel Growth Optimism at Lion

Updated Category News Views 34

Striking Copper: Panning Out or Fools' Gold? Well, here's a dose of copper digging straight from the heart of the Lion Zone with Power Metallic Mines (TSXV: PNPN, OTCBB: PNPNF) at the helm. Now, if copper's your game, the latest assay results might just tickle your fancy. We're talking hefty 13.30 meters at 3.98% CuEqRec in hole 26-115 and, get this, a juicy 5.26 meters...

Continue Reading